Viral status before and after initiation of rituximab therapy
Serologic parameters . | 12/29/2000, before chemotherapy . | 09/10/2002, 3 mo after initiation of rituximab . | 09/25/2002, 2 wk after initiation of lamivudine . |
|---|---|---|---|
| HbsAg* | Negative | Positive | Positive |
| HBV DNA, copies/mL | 50 ± 20† | 8.6 × 108 | 2.4 × 105 |
| Anti-HBs, IU/mL | > 1000 | 868 | > 1000 |
| Anti-HBc | Positive | Positive | Positive |
| Anti-HBc-IgM | NA | Negative | Negative |
Serologic parameters . | 12/29/2000, before chemotherapy . | 09/10/2002, 3 mo after initiation of rituximab . | 09/25/2002, 2 wk after initiation of lamivudine . |
|---|---|---|---|
| HbsAg* | Negative | Positive | Positive |
| HBV DNA, copies/mL | 50 ± 20† | 8.6 × 108 | 2.4 × 105 |
| Anti-HBs, IU/mL | > 1000 | 868 | > 1000 |
| Anti-HBc | Positive | Positive | Positive |
| Anti-HBc-IgM | NA | Negative | Negative |
HBsAg indicates hepatitis B surface antigen; HBV DNA, hepatitis B virus DNA; anti-HBs, antibodies against hepatitis B surface antigen; anti-HBc, antibodies against hepatitis B core antigen; IgM, immunoglobulin M; and NA, not available.
AxSym assay (Abbott Laboratories, Abbott Park, IL), 3 of 8 different commercially available test kits failed to detect the mutated HbsAg.
Real-time PCR8 performed in 2002.